m+Medelevator.RU
← Поиск публикаций
Advanced materials (Deerfield Beach, Fla.) · 2026

Hypoxia-Tolerant Supramolecular Nanomicelles for Pyroptosis-Enhanced NIR-II Phototheranostics.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Wang Xing, Dong Kunyan, Wang Zhichao, Tang Yuqi, Li Quan

Аннотация

Tumor hypoxia, limited solid-tumor imaging, and insufficient systemic antitumor immunity remain major challenges to effective cancer phototheranostics. Here, a molecular conformation engineering strategy is developed to construct TBBP, which features a strengthened electron donor, a moderately twisted conformation, extended π-conjugation, and a robust molecular skeleton free of labile olefinic π-bridges. TBBP exhibits excellent photostability, broadband second near-infrared (1000-1600 nm) emission, and efficient photothermal conversion (42.17%). Supramolecular assembly with DSPE-PEG2000 affords stable TBBP nanomicelles, TBBP NPs, that selectively generate superoxide radicals (O2 -•) and retain potent Type I photodynamic therapy (PDT) activity under hypoxia. Photoactivated TBBP NPs further induce mitochondrial dysfunction and caspase-3/GSDME-mediated immunogenic pyroptosis, promoting dendritic cell maturation and CD8+ T cell infiltration. In a bilateral 4T1 tumor model, TBBP NPs enable high-contrast second near-infrared (NIR-II) imaging, while synergistic Type I PDT and photothermal therapy elicit systemic antitumor immunity, achieving 92.0% primary tumor inhibition and 47.7% distant tumor inhibition. This work establishes a molecular conformation engineering strategy and extends its functionality through supramolecular assembly, synergistically integrating NIR-II imaging, hypoxia-tolerant Type I phototherapy, and photoimmunotherapy, thereby providing a generalizable molecular design principle for the development of next-generation multifunctional organic phototheranostic agents.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты